ABIOMED

ABIOMED EBIT

Delisted

The EBIT of ABIOMED (ABMD) as of Nov 12, 2026 is 140.72 M USD. In the previous year, EBIT was 229.56 M USD — a change of -38.70% (lower).

EBIT

140.72 MUSD

YoY

-38.70%

Last updated:

In 2022, ABIOMED's EBIT was 140.72 M USD, a -38.70% increase from the 229.56 M USD EBIT recorded in the previous year.

The ABIOMED EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2020
249.22 M USD
Jan 1, 2021
229.56 M USD
Jan 1, 2022
140.72 M USD
Jan 1, 2023 (e)
271.28 M USD
Jan 1, 2024 (e)
333.59 M USD
Jan 1, 2025 (e)
408.50 M USD
Jan 1, 2026 (e)
470.09 M USD
Jan 1, 2027 (e)
510.11 M USD
The ABIOMED EBIT history
YEAREBITYoY
est510.11 MUSD+8.51%
est470.09 MUSD+15.08%
est408.50 MUSD+22.46%
est333.59 MUSD+22.97%
est271.28 MUSD+92.78%
140.72 MUSD-38.70%
229.56 MUSD-7.89%
249.22 MUSD+10.86%
224.81 MUSD+43.07%
157.14 MUSD+74.33%
90.14 MUSD+38.45%
65.10 MUSD+127.11%
28.67 MUSD+242.77%
8.36 MUSD-49.45%
16.54 MUSD+988.36%
1.52 MUSD-113.59%
-11.19 MUSD-55.40%
-25.08 MUSD-15.05%
-29.52 MUSD-19.10%
-36.49 MUSD+27.98%
-28.51 MUSD-5.88%
-30.29 MUSD+831.17%
-3.25 MUSD-68.27%
-10.25 MUSD-47.40%
-19.49 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ABIOMED Revenue

ABIOMED Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
840.88 M USD
249.22 M USD
203.01 M USD
Jan 1, 2021
847.52 M USD
229.56 M USD
225.53 M USD
Jan 1, 2022
1.03 B USD
140.72 M USD
136.51 M USD
Jan 1, 2023 (e)
1.14 B USD
271.28 M USD
0.00 USD
Jan 1, 2024 (e)
1.36 B USD
333.59 M USD
0.00 USD
Jan 1, 2025 (e)
1.54 B USD
408.50 M USD
321.51 M USD
Jan 1, 2026 (e)
1.71 B USD
470.09 M USD
374.32 M USD
Jan 1, 2027 (e)
1.81 B USD
510.11 M USD
448.54 M USD

ABIOMED Margins

ABIOMED stock margins

The ABIOMED margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ABIOMED. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ABIOMED.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
82.01 %
29.64 %
24.14 %
Jan 1, 2021
80.90 %
27.09 %
26.61 %
Jan 1, 2022
81.76 %
13.64 %
13.23 %
Jan 1, 2023 (e)
81.76 %
23.73 %
0.00 %
Jan 1, 2024 (e)
81.76 %
24.58 %
0.00 %
Jan 1, 2025 (e)
81.76 %
26.53 %
20.88 %
Jan 1, 2026 (e)
81.76 %
27.47 %
21.88 %
Jan 1, 2027 (e)
81.76 %
28.18 %
24.78 %

ABIOMED Stock analysis

What does ABIOMED do? Abiomed Inc. is one of the most innovative companies in the medical technology industry. It was founded in 1981 and is headquartered in Danvers, Massachusetts. The company specializes in the development, manufacturing, and marketing of medical devices aimed at saving or improving patients' lives. Abiomed started as a small company focused on implantation technology for cardiac arrhythmias. However, the company soon recognized the need to concentrate on providing solutions for cardiac intensive care. Today, Abiomed is a leader in the field of cardiopulmonary support systems and offers innovative devices to support the heart. Abiomed's business model revolves around leveraging its expertise in medical technology for cardiology interventions and intensive care and bringing innovative products to market. The company has industry experts and doctors on its team who contribute to the development and manufacturing of products. This highest level of professionalism is also reflected in the distribution channels Abiomed utilizes, with a focus on delivering its products to clinics specialized in critical medical interventions. Abiomed is divided into various business segments that concentrate on the medical devices the company offers. One of these segments is the Impella portfolio, which focuses on heart pumps for acute heart failure. These pumps are capable of supporting the heart during cardiological intervention by pumping blood into the heart while artificially ventilating it. The Impella portfolio is recognized as a standard in cardiac intensive care. Another important area for Abiomed is product development. The company heavily invests in researching and developing new products to meet the current demand in cardiology on the market. Abiomed is aware that rapid development of new products can provide a competitive advantage and, therefore, is an essential part of its business model. The technology offered by Abiomed is revolutionary and allows for the treatment of patients with acute heart failure, which was previously difficult or impossible. This is a significant milestone for the company and the healthcare industry in general. Abiomed is aware of its responsibility towards patients, doctors, and hospitals and is continuously working to develop innovative solutions for the healthcare industry. In summary, Abiomed Inc. is a leading company in the medical technology industry that focuses on cardiology intervention and intensive care. The company is innovative and offers products that can save and improve patients' lives. The Impella portfolio, specializing in acute heart failure, is an important part of its business model. Abiomed heavily invests in research and development to consistently provide innovative solutions to its customers. ABIOMED is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing ABIOMED's EBIT

ABIOMED's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of ABIOMED's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

ABIOMED's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in ABIOMED’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about ABIOMED stock

EBIT of ABIOMED is 140.72 M USD in 2022.

EBIT of ABIOMED changed from 229.56 M USD to 140.72 M USD, representing a -38.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT ABIOMED since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's ABIOMED historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ABIOMED

All Key Metrics — ABIOMED